News
Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...
Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback